Scientists at Rutgers Health have discovered that a molecule produced by certain gut bacteria can rapidly heal intestinal damage in mice and fruit flies, according to a study published in Science Advances. The molecule, known as (amide-)N-methylnicotinamide or N-MNA, works by activating a coenzyme called nicotinamide adenine dinucleotide (NAD), whose declining levels are thought to be a key driver of the aging process.

In tests conducted on mice, fruit flies, and human cells, the research team found that N-MNA acts as a precursor to NAD, stimulating stem cell regeneration in the gut lining and accelerating repair of damaged tissue. The findings offer a potential new approach to treating inflammatory bowel disease (IBD) and other chronic gut disorders in humans, though the researchers caution that clinical applications remain years away.

“Humans do not appear to make this exact precursor molecule N-MNA, but some of the bacteria living in our gut do,” said senior study author Nan Gao, a professor of pharmacology, physiology and neuroscience at Rutgers New Jersey Medical School, in a university news release.

N-MNA is structurally very similar to a molecule that human cells produce when they dispose of excess NAD building blocks. The key difference, according to the researchers, is that the bacterial version can be converted back into NAD, whereas the human-made molecule cannot.

“The molecules animal cells and bacteria make are almost identical, but a tiny difference allows the creation of the bacterial compound back into NAD itself,” said Xiaoyang Su, associate professor of medicine at Rutgers Robert Wood Johnson Medical School and another senior author of the study.

Jiangmeng Han, the first author and a doctoral student in biological sciences at Rutgers University-Newark, tracked the molecule into human colon cells, where it supplied about 22% of their NAD within 24 hours. The molecule also became NAD in human neurons, liver cells, and kidney cells, as well as in the bodies and heads of fruit flies that were given the compound.

In experiments with mice that had inflamed and damaged colons, untreated animals lost 20% of their body weight and died, while those injected with N-MNA lost only 5% and recovered. In fruit flies with damaged guts, N-MNA raised seven-day survival from 43% to 78%.

The researchers also analyzed stool samples from 54 patients with IBD and 20 healthy volunteers. Patients with low levels of N-MNA had significantly higher markers of gut inflammation. “Patients with low levels of this metabolite showed a higher inflammatory activity,” Gao said. He suggested that a stool test might eventually help identify patients likely to benefit from probiotics, though that application is probably several years away.

The study did not test N-MNA treatment directly in IBD patients, nor did it examine whether consuming probiotic strains that produce N-MNA—including Lactobacilli found in yogurt and oral supplements—raises NAD levels in humans. “This compound itself may be sufficient, but we cannot rule out the possibility that there are other, better compounds,” said Ching-On Wong, an assistant professor of biological sciences at Rutgers-Newark and a senior author who contributed fly genetics expertise to the study.

Gao emphasized that the research is still at a fundamental stage. “Right now, we’re still trying to understand the fundamentals, and this requires a multidisciplinary team of a biochemist, fly geneticist, and intestinal biologist,” he said.

A five-year, $3.6 million grant from the National Institutes of Health has been awarded to the team to find the human enzymes that break down N-MNA, which are not yet known. Wong's laboratory is investigating whether this molecule supports brain-cell health and longevity, while Gao's laboratory is identifying the bacterial genes responsible for its production. Rutgers has submitted a provisional patent application covering uses of N-MNA, listing Han, Ferraris, Su, and Gao as inventors.

The research was funded by the National Center for Complementary and Integrative Health, part of the National Institutes of Health, under grant number R01AT013333. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.